I am familiar with the published stats @Erneter, and consulted...

I am familiar with the published stats @Erneter, and consulted the 34-page Clinical Development Success Rates and Contributing Factors 2011–2020 done by the Biolotechnology Innovation Organisation which Hottod posted several months ago that I saved.

The way I see it is this.... IF PTX100 makes it through to a trucated Phase 3 trial (aka a registrational or pivotal trial) then PTX will get a valuable re-rate and then the likelihood of approval % dramatically improves. And, ODD also increases the likelihood % as per MrWayne's last post. With that said, though, as much as I would like to see PTX100 get to market, it is big stretch and I'm certainly not pinning hopes on anything that far down the track. There's enough in the nearterm newslow pipeline to re-rate the company's valuation, IMO.

Besides, I think the true value in PTX100 could be i its mechanism of action applicable to an undetermined number of cancers including solid tumors. That remains to be investigated (or disclosed fully to the market). In the meantime, I am happy with the company looking like it will be able to pursue the next phase towards commercialisation.

Re OmniCAR, I assume our collabs with TFS and MD Anderson fall short of your high expectations and standards for some reason. Thats a shame, because I see our blossoming network as our lifeline to success.